--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About SEPN20260918C41
Biotechnology Ⅲ
Septerna, Inc., was incorporated in Delaware in December 2019 under the name GPCR NewCo, Inc. In June 2021, they changed their name to Septerna, Inc. The company is a clinical-stage biotechnology company that has ushered in a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, powered by its proprietary Native Complex PlatformTM. Their industrial-scale platform aims to unlock the full potential of GPCR therapies and discover and develop their deep pipeline of product candidates, initially focusing on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
